Address of Corresponding Author

Intervirology 2005;48:39-45 (DOI: 10.1159/000082093)

  Key Words

• Lectin-reactive alpha-fetoprotein
• Chemoprevention
• Clonal deletion
• Protein induced by vitamin K absence or antagonist-II
• Retinoid

  Abstract

Oral administration with acyclic retinoid, a synthetic vitamin A analog, for a limited period of 12 months (48 weeks) prevented the development of second primary hepatocellular carcinoma (HCC) and also improved the survival of patients who underwent curative treatments of the initial tumor. Following that randomized controlled study reported in 1996 and 1999, we have continued to follow up the patients by medical imaging and blood chemical analyses, and found that the preventive effect of acyclic retinoid lasted up to 199 weeks after randomization (or 151 weeks after completion of retinoid administration). The retinoid's effect was not mediated by reduction in hepatic necro-inflammation since no significant decrease in serum aminotransferase activity was seen in the retinoid group. Such observation seems quite distinct from the cancer-preventive mechanism of interferon, a potent immunopreventive agent for HCC. We have also shown here the reduction by the retinoid in serum levels of lectin-reactive -fetoprotein (AFP-L3) and protein induced by vitamin K absence or antagonist-II (PIVKA-II), both of which indicate the presence of latent HCC cells. These results suggest that acyclic retinoid may delete such malignant clones before they expand to clinically detectable tumors and thereby inhibited second primary HCC. Once such latent clones are eradicated, it may well take at least several years for the next cancer clone to arise clinically. This may possibly explain a reason for the long-term effect of the retinoid even after the limited period of administration.

Copyright © 2005 S. Karger AG, Basel

  References

1.

Hong WK, Lippman SM, Hittelman WN, Lotan R: Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin Cancer Res 1995;1:677-686.

2.

Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M, Omata M: Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995;22:1027-1033.

3.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Takayama T, Kawasaki S, Makuuchi M: Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207.

4.

Yamada Y, Shidoji Y, Fukutomi Y, Ishikawa T, Kameko T, Nakagama H, Imawari M, Moriwaki H, Muto Y: Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994;10:151-158.

5.

Araki H, Shidoji Y, Yamada Y, Moriwaki H, Muto Y: Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 1995;209:66-72.

6.

Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, Seishima M, Muto Y, Moriwaki H: Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002;36:660-671.

7.

Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-1567.

8.

Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-1047.

9.

Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekiya C, Igarashi K, Ichida F: The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988;61:769-774.

10.

Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, Taketa K, Nagataki S: Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993;328:1802-1806.

11.

Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T: A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22:802-807.

12.

Ikoma J, Kaito M, Ishihara T, Nakagawa M, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y: Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: A prospective study. Hepatogastroenterology 2002;49:235-238.

13.

Moriwaki H, Yasuda I, Shiratori Y, Uematsu T, Okuno M, Muto Y: Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: A potent biomarker in the chemoprevention of second primary hepatoma. Clin Cancer Res 1997;3:727-731.

14.

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano Y, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Ann Intern Med 1999;131:174-181.

15.

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K, Osaka liver disease study group: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.

16.

Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL, Moriwaki H: Acyclic retinoid in the chemoprevention of hepatocellular carcinoma. Int J Oncol 2004;24:797-805.

17.

Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, Friedman SL, Kojima S: Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001;61:7675-7682.

18.

Adachi S, Okuno M, Matsushima-Nishiwaki R, Takano Y, Kojima S, Friedman SL, Moriwaki H, Okano Y: Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002;35:332-340.

19.

Suzui M, Masuda M, Lim JTE, Albanes C, Pestell RG, Weinstein IB: Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21^CIP1 and inhibition of expression of cyclin D1. Cancer Res 2002;62:3997-4006.

20.

Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, Yasuda I, Yamada Y, Akita K, Sano T, Shimada J, Kojima S, Okano Y, Friedman SL, Moriwaki H: Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002;36:1115-1124

21.

Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H: Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003;24:1353-1359.

  Author Contacts

Hisataka Moriwaki, MD
Department of Gastroenterology
Gifu University School of Medicine
Gifu 501-1194 (Japan)
Tel./Fax +81 58 230 6313, E-Mail hmori@cc.gifu-u.ac.jp

  Article Information

Number of Print Pages : 7
Number of Figures : 4, Number of Tables : 2, Number of References : 21

  Publication Details

Intervirology (International Journal of Basic and Medical Virology)

Vol. 48, No. 1, Year 2005 (Cover Date: 2005)

Journal Editor: U.G. Liebert, Leipzig
ISSN: 0300-5526 (print), 1423-0100 (Online)

For additional information: http://www.karger.com/int

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.